Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly & Co. stock underperforms Tuesday when compared to competitors
Shares of Eli Lilly & Co. LLY sank 0.08% to $795.67 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.10% to 6,040.04 and the Dow Jones Industrial Average DJIA rising 0.91% to 43,297.03.
Eli Lilly Stock Is Rising Monday: What's Going On?
Eli Lilly and Company (NYSE: LLY) shares are trading higher Monday. The upward momentum in the stock comes after the FDA approved the company's Zepbound, a weight loss drug designed to treat moderate-to-severe obstructive sleep apnea in adults with obesity.
Analyst: Outperforming Netflix Stock Has More in the Tank
The new price target represents a nearly 10% premium to Netflix stock's current perch of $915.31 and is just above its Dec. 11 all-time high of $941.75. The equity is up 87.7% since the start of 2024,
Netflix Inc. stock rises Monday, still underperforms market
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with unparalleled accuracy. Back To Top
1d
on MSN
Eli Lilly, Novo Nordisk Stocks Rise. Only One Is Operating From a Position of Strength.
The obesity drug race is heating up in more ways than one.Eli Lilly, the world’s biggest pharmaceutical company by market ...
6d
This Is Huge News for Eli Lilly Investors
Eli Lilly just gave investors several reasons to cheer.
4d
The FDA just approved Eli Lilly's Zepbound for sleep apnea — and Medicare coverage could be next
Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...
1d
Eli Lilly, Qualcomm, Rumble: Market Minute
Yahoo Finance host Akiko Fujita highlights three of the top trending stocks and stories as part of today's Market Minute.
7d
Eli Lilly Is Putting Dividend Growth Stocks to Shame With Yet Another Huge Increase to Its Payout
What Eli Lilly ( LLY -0.05%) is doing is far more impressive. The company has been increasing its dividend at a high rate, ...
4d
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?
Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...
3d
on MSN
Novo Nordisk raises expectations for Eli Lilly after CagriSema slipup
Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...
1d
Eli Lilly ‘commends’ ITC ruling cracking down on unlawful tirzepatide imports
In a win for patients, the judge overseeing Lilly’s International Trade Commission case determined that U.S. Customs ...
3d
Eli Lilly to test weight loss drug Zepbound to treat addiction
Weight loss injections have become a popular choice to help people curb their appetite, but can they curb addiction, as well?
1d
Retail investors buy Novo dip after disappointing weight-loss drug data
U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Zepbound
Sleep apnea
Russia
United States
Honda
Feedback